BibTex RIS Cite

Primer katastrofik antifosfolipid sendrom: 8 yaşında kız çocuk

Year 2016, Volume: 29 Issue: 1, 41 - 44, 04.03.2016
https://doi.org/10.5472/MMJcr.2901.07

Abstract

Antifosfolipid antikor sendromu (AFAS) tekrarlayan venöz ve
arteriyel trombozlarla seyreden bir hastalıktır. Hastaların %1’inden
azında görülen hızlı seyirli, çoklu trombozlara bağlı multiorgan
yetmezlik tablosu katastrofik antifosfolipid antikor sendromu
(KAFAS) olarak adlandırılmaktadır. Burada eritematöz cilt
lezyonlarıyla başvuran, takibinde alt ekstremitelerde yaygın purpura
fulminans gelişen 8 yaşında kız çocuk sunulmaktadır. Hastada
cilt tutulumuna ek olarak izlemde proteinüri, mikroanjiyopatik
hemolitik anemiye eşlik eden trombositopeni gelişmesi ve cilt
biyopsilerinde arteryel ve venöz trombozlar gösterilmesi nedeniyle
KAFAS geliştiği düşünüldü. Hastaya yoğun bakım desteği ve
geniş spektrumlu antimikrobiyal tedavilerin yanısıra antikoagulan,
antiagregan, steroid, intravenöz immünoglobulin tedavileri
uygulandı. Bu aşamada hastada lupus antikoagulan, anti beta-2
glikoprotein ve antifosfolipid IgG pozitifliği saptanması üzerine
AFAS tanısı doğrulandı. Ancak etiyolojiye yönelik araştırmalarda
trombotik riski düşük MTHFR-A1298C, MTHFR-C677T, faktör
V H1299R, beta fibrinojen-455 G>A mutasyonlarının heterozigot
pozitifliği dışında romatolojik, enfeksiyöz ve malign nedenler
saptanmadı. Aile öyküsünde; ablada Raynaud fenomeni, halada
benzer cilt lezyonları, babaannede intersitisyel akciğer hastalığı ve
proteinüri olmasının yanında baba ve iki ablada lupus antikoagulan
pozitifliği saptandı. Yaygın cilt nekrozuna yönelik debridman,
greftleme ve lokal mezankimal kök hücre tedavisinin yanısıra
azatioprin tedavileri de uygulanan hastada cilt bulgularında
belirgin düzelme gözlendi.

References

  • 1. Chalmers E, Cooper P, Forman K, et al. Purpura fulminans: recognition, diagnosis and management. Arch Dis Child 2011; 96:1066-71. doi: 10.1136/adc.2010.199919
  • 2. Gezer S. Antiphospholipid syndrome. Dis Mon 2003;49:696– 741. doi: 10.1016/j.disamonth.2003.10.001 3. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992;19: 508-12.
  • 4. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998;77:195-207. doi:10.1097/00005792-199805000-00005
  • 5. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002;46:1019–27. doi: 10.1002/art.10187
  • 6. Gomes FH, Carvalho L, Pinheiro P, et al. A16: Long-term follow-up of 36 Pediatric Antiphospholipid Syndrome Patients: A Retrospective Study. Arthritis Rheum 2014; 66:S26. doi: 10.1002/art.38432
  • 7. Asherson R. New subsets of the antiphospholipid syndrome in 2006: “PRE-APS” (probable APS) and microangiopathic antiphospholipid syndromes (“MAPS”). Autoimmun Rev 2006;6:76–80. doi:10.1016/j.autrev.2006.06.008
  • 8. Asherson R, Cervera R, Shoenfeld Y, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003;12:530-4. doi: 10.1191/0961203303lu394oa
  • 9. Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 2010;10:74-9. doi:10.1016/j.autrev.2010.08.005
  • 10. DiFrancesco LM, Burkart P, Hoehn JG. A cutaneous manifestation of antiphospholipid antibody syndrome. Ann Plast Surg 2003;51:517-22.
  • 11. Berman H, Rodríguez-Pintó I, Cervera R, et al. Pediatric catastrophic antiphospholipid syndrome: Descriptive analysis of 45 patients from the “CAPS Registry”. Autoimmun Rev 2014;13:157-62. doi:10.1016/j.autrev.2013.10.004
  • 12. Brouwer JL, Bijl M, Veeger NJ, et al. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004;104:143-8. doi: http://dx.doi. org/10.1182/blood-2003-11-4085
  • 13. Galli M, Finazzi G, Duca F, et al. The G1691 --> A mutation of factor V, but not the G20210 --> A mutation of factor II or the C677 --> T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants. Br J Haematol 2000;108:865-70. doi: 10.1046/j.1365-2141.2000.01964.x
  • 14. Avcin T, Cimaz R, Rozman B. Ped-APS Registry Collaborative Group. The Ped-APS Registry: the antiphospholipid syndrome in childhood. Lupus 2009;18:894- 9. doi: 10.1177/0961203309106917
  • 15. Cervera R. CAPS Registry. Lupus 2012;21(7):755-7. doi: 10.1177/0961203312436866.
  • 16. Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”. Semin Thromb Hemost 2012;38:333-8. doi: 10.1055/s-0032- 1304718
Year 2016, Volume: 29 Issue: 1, 41 - 44, 04.03.2016
https://doi.org/10.5472/MMJcr.2901.07

Abstract

References

  • 1. Chalmers E, Cooper P, Forman K, et al. Purpura fulminans: recognition, diagnosis and management. Arch Dis Child 2011; 96:1066-71. doi: 10.1136/adc.2010.199919
  • 2. Gezer S. Antiphospholipid syndrome. Dis Mon 2003;49:696– 741. doi: 10.1016/j.disamonth.2003.10.001 3. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992;19: 508-12.
  • 4. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998;77:195-207. doi:10.1097/00005792-199805000-00005
  • 5. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002;46:1019–27. doi: 10.1002/art.10187
  • 6. Gomes FH, Carvalho L, Pinheiro P, et al. A16: Long-term follow-up of 36 Pediatric Antiphospholipid Syndrome Patients: A Retrospective Study. Arthritis Rheum 2014; 66:S26. doi: 10.1002/art.38432
  • 7. Asherson R. New subsets of the antiphospholipid syndrome in 2006: “PRE-APS” (probable APS) and microangiopathic antiphospholipid syndromes (“MAPS”). Autoimmun Rev 2006;6:76–80. doi:10.1016/j.autrev.2006.06.008
  • 8. Asherson R, Cervera R, Shoenfeld Y, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003;12:530-4. doi: 10.1191/0961203303lu394oa
  • 9. Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 2010;10:74-9. doi:10.1016/j.autrev.2010.08.005
  • 10. DiFrancesco LM, Burkart P, Hoehn JG. A cutaneous manifestation of antiphospholipid antibody syndrome. Ann Plast Surg 2003;51:517-22.
  • 11. Berman H, Rodríguez-Pintó I, Cervera R, et al. Pediatric catastrophic antiphospholipid syndrome: Descriptive analysis of 45 patients from the “CAPS Registry”. Autoimmun Rev 2014;13:157-62. doi:10.1016/j.autrev.2013.10.004
  • 12. Brouwer JL, Bijl M, Veeger NJ, et al. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004;104:143-8. doi: http://dx.doi. org/10.1182/blood-2003-11-4085
  • 13. Galli M, Finazzi G, Duca F, et al. The G1691 --> A mutation of factor V, but not the G20210 --> A mutation of factor II or the C677 --> T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants. Br J Haematol 2000;108:865-70. doi: 10.1046/j.1365-2141.2000.01964.x
  • 14. Avcin T, Cimaz R, Rozman B. Ped-APS Registry Collaborative Group. The Ped-APS Registry: the antiphospholipid syndrome in childhood. Lupus 2009;18:894- 9. doi: 10.1177/0961203309106917
  • 15. Cervera R. CAPS Registry. Lupus 2012;21(7):755-7. doi: 10.1177/0961203312436866.
  • 16. Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”. Semin Thromb Hemost 2012;38:333-8. doi: 10.1055/s-0032- 1304718
There are 15 citations in total.

Details

Primary Language English
Journal Section Articles
Authors

Hatice Ezgi Baris This is me

Cisem Aksu Lımon This is me

Cisem Aksu Limon This is me

Irmak Vural This is me

Eda Kepenekli This is me

Eda Kepenekli This is me

Ahmet Koc This is me

Ayca Kıykım This is me

Ayca Kiykim This is me

Deniz Yucelten This is me

Deniz Yucelten This is me

Ozgur Kasapcopur This is me

Ozgur Kasapcopur This is me

Safa Baris This is me

Safa Barıs This is me

Elif Karakoc Aydıner This is me

Elif Karakoc-aydiner This is me

Ahmet Ozen This is me

İsil Barlan This is me

Isil Barlan This is me

Publication Date March 4, 2016
Published in Issue Year 2016 Volume: 29 Issue: 1

Cite

APA Baris, H. E., Aksu Lımon, C., Aksu Limon, C., Vural, I., et al. (2016). Primer katastrofik antifosfolipid sendrom: 8 yaşında kız çocuk. Marmara Medical Journal, 29(1), 41-44. https://doi.org/10.5472/MMJcr.2901.07
AMA Baris HE, Aksu Lımon C, Aksu Limon C, Vural I, Kepenekli E, Kepenekli E, Koc A, Kıykım A, Kiykim A, Yucelten D, Yucelten D, Kasapcopur O, Kasapcopur O, Baris S, Barıs S, Karakoc Aydıner E, Karakoc-aydiner E, Ozen A, Barlan İ, Barlan I. Primer katastrofik antifosfolipid sendrom: 8 yaşında kız çocuk. Marmara Med J. March 2016;29(1):41-44. doi:10.5472/MMJcr.2901.07
Chicago Baris, Hatice Ezgi, Cisem Aksu Lımon, Cisem Aksu Limon, Irmak Vural, Eda Kepenekli, Eda Kepenekli, Ahmet Koc, Ayca Kıykım, Ayca Kiykim, Deniz Yucelten, Deniz Yucelten, Ozgur Kasapcopur, Ozgur Kasapcopur, Safa Baris, Safa Barıs, Elif Karakoc Aydıner, Elif Karakoc-aydiner, Ahmet Ozen, İsil Barlan, and Isil Barlan. “Primer Katastrofik Antifosfolipid Sendrom: 8 yaşında kız çocuk”. Marmara Medical Journal 29, no. 1 (March 2016): 41-44. https://doi.org/10.5472/MMJcr.2901.07.
EndNote Baris HE, Aksu Lımon C, Aksu Limon C, Vural I, Kepenekli E, Kepenekli E, Koc A, Kıykım A, Kiykim A, Yucelten D, Yucelten D, Kasapcopur O, Kasapcopur O, Baris S, Barıs S, Karakoc Aydıner E, Karakoc-aydiner E, Ozen A, Barlan İ, Barlan I (March 1, 2016) Primer katastrofik antifosfolipid sendrom: 8 yaşında kız çocuk. Marmara Medical Journal 29 1 41–44.
IEEE H. E. Baris, “Primer katastrofik antifosfolipid sendrom: 8 yaşında kız çocuk”, Marmara Med J, vol. 29, no. 1, pp. 41–44, 2016, doi: 10.5472/MMJcr.2901.07.
ISNAD Baris, Hatice Ezgi et al. “Primer Katastrofik Antifosfolipid Sendrom: 8 yaşında kız çocuk”. Marmara Medical Journal 29/1 (March 2016), 41-44. https://doi.org/10.5472/MMJcr.2901.07.
JAMA Baris HE, Aksu Lımon C, Aksu Limon C, Vural I, Kepenekli E, Kepenekli E, Koc A, Kıykım A, Kiykim A, Yucelten D, Yucelten D, Kasapcopur O, Kasapcopur O, Baris S, Barıs S, Karakoc Aydıner E, Karakoc-aydiner E, Ozen A, Barlan İ, Barlan I. Primer katastrofik antifosfolipid sendrom: 8 yaşında kız çocuk. Marmara Med J. 2016;29:41–44.
MLA Baris, Hatice Ezgi et al. “Primer Katastrofik Antifosfolipid Sendrom: 8 yaşında kız çocuk”. Marmara Medical Journal, vol. 29, no. 1, 2016, pp. 41-44, doi:10.5472/MMJcr.2901.07.
Vancouver Baris HE, Aksu Lımon C, Aksu Limon C, Vural I, Kepenekli E, Kepenekli E, Koc A, Kıykım A, Kiykim A, Yucelten D, Yucelten D, Kasapcopur O, Kasapcopur O, Baris S, Barıs S, Karakoc Aydıner E, Karakoc-aydiner E, Ozen A, Barlan İ, Barlan I. Primer katastrofik antifosfolipid sendrom: 8 yaşında kız çocuk. Marmara Med J. 2016;29(1):41-4.